Yale Researchers Find Gaps in Clinical Trial Data Sharing
Since the late 1990s, Congress and federal agencies have increased requirements for pharmaceutical companies to register and report results from clinical trials. Yet, some companies don’t fully comply with the rules and industry guidelines vary.Source: YaleNews
Countries Denied Access to Medicines and Vaccines They Help Develop
A Yale-led study reveals that new medicines and vaccines approved for use in the United States are often unavailable in countries that hosted their clinical trials, suggesting that the benefits of drug research are not being shared equitably among populations that participate in testing.Source: YaleNews
Good Pharma Scorecard Continues to Boost Clinical Trial Transparency, Analyst Report Shows
Calls for increased transparency in clinical trials have been growing and now many medical journals are requiring authors of submitted papers to disclose whether or not they will be sharing clinical trial results.Source: Biospace
Some Big Pharmas stepped up their game on data transparency — but which flunked the test?
The nonprofit Bioethics International has come out with their latest scorecard on data transparency among the big biopharmas in the industry — flagging a few standouts while spotlighting some laggards who are continuing to underperform.Source: Endpoints News
Yale-developed Scorecard Promotes Better Clinical Trial Data Sharing
A tool developed by researchers at Yale, Stanford, and Bioethics International can promote greater sharing of clinical trial data by pharmaceutical companies. While nearly one-third of the companies that the researchers assessed met standards for sharing data, others could be more transparent to the benefit of science and the public, the researchers said.